68-Ga FAPI 46
Alternative Names: 68Ga-FAPi-46; [68Ga]FAPI-46Latest Information Update: 09 May 2025
At a glance
- Originator University of Heidelberg
- Developer SOFIE; University of California
- Class Antineoplastics; Imaging agents; Quinolines; Radioisotopes; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pancreatic cancer
- No development reported Breast cancer; Cholangiocarcinoma; Gastric cancer; Interstitial lung diseases; Ovarian cancer
Most Recent Events
- 05 May 2025 Erasmus Medical Center plans a clinical trial for Peritoneal metastases (Diagnosis) (IV) in September 2025 (NCT06957782)
- 11 Apr 2025 GE Healthcare plans a phase I trial for Solid tumours in USA (IV) (NCT06922825)
- 28 Dec 2024 No recent reports of development identified for phase-0 development in Interstitial lung diseases(Diagnosis) in USA (IV)